molecules of the month


p97/VCP ATPase inhibitor (PDE6 off-target)

Ph. I in cancer (discont., dyschromatopsia)

from HTS of NIH compound library

J. Pharmacol. Exp. Ther., Apr. 30, 2021

Cleave Therapeutics, San Francisco, CA

1 min read

The Cleave Therapeutics p97 (VCP) inhibitor, CB-5083, was a Ph. I clinical candidate for cancer that was terminated due to vision side effects including causing patients to see unusual colors (dyschromatopsia). In this paper, the authors suggest that the visual impairment was due to the compounds inhibition of the phosphodiesterase-6 (PDE6), which is involved in photoreceptor signal transduction. Fortunately, the effect on vision appears to be reversible, and the authors suggest CB-5083 should be re-evaluated in the clinic. This work suggests that PDE6 should be a more routinely screened against off-target, and preclinical ERG recordings can be used to assess functional safety relevance for compounds with in vitro PDE6 signals.

request a trial

Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.

Request a trial to access insights powering the pros in our industry.

already a member? log in: